BIOMAT Database Logo BIOMAT Database Logo

Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety. 2006

Udo E W Lange, and Dorit Baucke, and Wilfried Hornberger, and Helmut Mack, and Werner Seitz, and H Wolfgang Höffken
Abbott GmbH & Co. KG, D-67061 Ludwigshafen, Germany. udo.lange@abbott.com

Synthesis and SAR of orally active thrombin inhibitors of the d-Phe-Pro-Arg type with focus on the P2-moiety are described. The unexpected increase in in vitro potency, oral bioavailability, and in vivo activity of inhibitors with dehydroproline as P2-isostere is discussed. Over a period of 24h the antithrombin activity of the most active inhibitors with IC(50)s in the nanomolar range was determined in dogs demonstrating high thrombin inhibitory activity in plasma and an appropriate duration of action after oral administration.

UI MeSH Term Description Entries
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000991 Antithrombins Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins. Antithrombin,Direct Antithrombin,Direct Antithrombins,Direct Thrombin Inhibitor,Direct Thrombin Inhibitors,Antithrombin, Direct,Antithrombins, Direct,Inhibitor, Direct Thrombin,Thrombin Inhibitor, Direct,Thrombin Inhibitors, Direct
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Udo E W Lange, and Dorit Baucke, and Wilfried Hornberger, and Helmut Mack, and Werner Seitz, and H Wolfgang Höffken
Orally active direct thrombin inhibitors.
May 2003, Seminars in vascular medicine,
Udo E W Lange, and Dorit Baucke, and Wilfried Hornberger, and Helmut Mack, and Werner Seitz, and H Wolfgang Höffken
Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif.
May 2008, Bioorganic & medicinal chemistry letters,
Udo E W Lange, and Dorit Baucke, and Wilfried Hornberger, and Helmut Mack, and Werner Seitz, and H Wolfgang Höffken
Progress towards the discovery of orally active thrombin inhibitors.
December 1998, Current medicinal chemistry,
Udo E W Lange, and Dorit Baucke, and Wilfried Hornberger, and Helmut Mack, and Werner Seitz, and H Wolfgang Höffken
Challenges in the development of orally bioavailable thrombin active site inhibitors.
September 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
Udo E W Lange, and Dorit Baucke, and Wilfried Hornberger, and Helmut Mack, and Werner Seitz, and H Wolfgang Höffken
Direct thrombin inhibitors (part 2 of 2).
February 2005, The Journal of invasive cardiology,
Udo E W Lange, and Dorit Baucke, and Wilfried Hornberger, and Helmut Mack, and Werner Seitz, and H Wolfgang Höffken
Retro-binding thrombin active site inhibitors: identification of an orally active inhibitor of thrombin catalytic activity.
November 2002, Bioorganic & medicinal chemistry letters,
Udo E W Lange, and Dorit Baucke, and Wilfried Hornberger, and Helmut Mack, and Werner Seitz, and H Wolfgang Höffken
The optimization of aminooxadiazoles as orally active inhibitors of Cdc7.
December 2013, Bioorganic & medicinal chemistry letters,
Udo E W Lange, and Dorit Baucke, and Wilfried Hornberger, and Helmut Mack, and Werner Seitz, and H Wolfgang Höffken
Direct thrombin inhibitors (part 1 of 2).
January 2005, The Journal of invasive cardiology,
Udo E W Lange, and Dorit Baucke, and Wilfried Hornberger, and Helmut Mack, and Werner Seitz, and H Wolfgang Höffken
Development of Orally Active Thrombin Inhibitors for the Treatment of Thrombotic Disorder Diseases.
June 2015, Molecules (Basel, Switzerland),
Udo E W Lange, and Dorit Baucke, and Wilfried Hornberger, and Helmut Mack, and Werner Seitz, and H Wolfgang Höffken
Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants.
September 2004, Current medicinal chemistry,
Copied contents to your clipboard!